Full Press Release Details
Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable
Webcast Scheduled to Begin at 8:00 a.m. ET Today
Mass., June 20, 2024 - Aldeyra Therapeutics,
Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated
and metabolic diseases, today announced advancement of new RASP modulators and recent preclinical data in obesity in conjunction with
an Investor Roundtable scheduled to begin at 8:00 a.m. ET today.
with the new data presented at our Research and Development Day in April of this year, we continue to expand our novel RASP modulator
pipeline with the discovery and advancement of new RASP modulators for the treatment of inflammatory and metabolic diseases," stated
Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra. "We look forward to discussing our recent progress
on today's call with investors and are excited to share subsequent updates on our pipeline throughout the remainder of 2024."
Roundtable Webcast Information
2024 Aldeyra Therapeutics Investor Roundtable will take place at 8:00 a.m. ET today, Thursday, June 20, 2024. A live audio webcast will
be accessible from the "Investors & Media" section of the Aldeyra website at https://ir.aldeyra.com/. A replay will be
available for 90 days following the event.
Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases.
Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein
targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive
aldehyde species) modulators ADX-629, ADX-248, ADX-743, ADX-631, and chemically related molecules for the potential treatment of systemic
and retinal immune-mediated and metabolic diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential
treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential
treatment of retinitis pigmentosa.
release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but
not limited to, statements regarding Aldeyra's future expectations, plans, and prospects, including without limitation statements
regarding: the goals, opportunity, and potential for Aldeyra's product candidates; the outcome and expected timing and the results
of Aldeyra's planned preclinical and clinical trials, including planned and ongoing trials; the outcome and timing of the FDA's
review, acceptance and/or approval of IND submissions for Aldeyra's product candidates. Aldeyra intends such forward-looking statements
to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of
1934 and the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such
as, but not limited to, "may," "might," "will," "objective," "intend," "should,"
"could," "can," "would," "expect," "believe," "anticipate," "project,"
"on track," "scheduled," "target," "design," "estimate," "predict,"
"contemplates," "likely," "potential," "continue," "ongoing," "aim,"
"plan," or the negative of these terms, and similar expressions intended to identify forward-looking statements. Such forward-looking
statements are based upon current expectations that involve risks, changes in circumstances, assumptions, and uncertainties. Aldeyra
is at an early stage of development and may not ever have any products that generate significant revenue. All of Aldeyra's development
timelines may be subject to adjustment depending on recruitment rate, regulatory review, preclinical and clinical results, funding, and
other factors that could delay the initiation, enrollment, or completion of clinical trials. Important factors that could cause actual
results to differ materially from those reflected in Aldeyra's forward-looking statements include, among others, the timing of enrollment,
commencement and completion of Aldeyra's clinical trials, the timing and success of preclinical studies and clinical trials conducted
by Aldeyra and its development partners; delay in or failure to obtain regulatory approval of Aldeyra's product candidates, including
as a result of the FDA not accepting Aldeyra's regulatory filings, issuing a complete response letter, or requiring additional
clinical trials or data prior to review or approval of such filings or in connection with resubmissions of such filings; the ability
to maintain regulatory approval of Aldeyra's product candidates, and the labeling for any approved products; the risk that prior results,
such as signals of safety, activity, or durability of effect, observed from preclinical or clinical trials, will not be replicated or
will not continue in ongoing or future studies or clinical trials involving Aldeyra's product candidates in clinical trials focused on
the same or different indications; the scope, progress, expansion, and costs of developing and commercializing Aldeyra's product candidates;
uncertainty as to Aldeyra's ability to commercialize (alone or with others) and obtain reimbursement for Aldeyra's product candidates
following regulatory approval, if any; the size and growth of the potential markets and pricing for Aldeyra's product candidates and
the ability to serve those markets; Aldeyra's expectations regarding Aldeyra's expenses and future revenue, the timing of future revenue,
the sufficiency or use of Aldeyra's cash resources and needs for additional financing; the rate and degree of market acceptance of any
of Aldeyra's product candidates; Aldeyra's expectations regarding competition; Aldeyra's anticipated growth strategies; Aldeyra's ability
to attract or retain key personnel; Aldeyra's commercialization, marketing and manufacturing capabilities and strategy; Aldeyra's
ability to establish and maintain development partnerships; Aldeyra's ability to successfully integrate acquisitions into its business;
Aldeyra's expectations regarding federal, state, and foreign regulatory requirements; political, economic, legal, social, and health
risks, public health measures, and war or other military actions, that may affect Aldeyra's business or the global economy; regulatory
developments in the United States and foreign countries; Aldeyra's ability to obtain and maintain intellectual property protection for
its product candidates; the anticipated trends and challenges in Aldeyra's business and the market in which it operates; and other factors
that are described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results
of Operations" sections of Aldeyra's Annual Report on Form 10-K for the year ended December 31, 2023 and
Aldeyra's Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, which are on file with the Securities and
Exchange Commission (SEC) and available on the SEC's website at https://www.sec.gov/. Additional factors may be described in those sections
of Aldeyra's Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, expected to be filed with the SEC in the third
quarter of 2024, and Aldeyra's other filings with the SEC.
addition to the risks described above and in Aldeyra's other filings with the SEC, other unknown or unpredictable factors also could
affect Aldeyra's results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements.
The information in this release is provided only as of the date of this release, and Aldeyra undertakes no obligation to update any forward-looking
statements contained in this release on account of new information, future events, or otherwise, except as required by law.
| Investor & Media Contact: |
| David Burke |
| Tel: (917) 618-2651 |
| investorrelations@aldeyra.com |